N6-Methyladenosine Regulators Are Involved in the Progression of and Have Clinical Impact on Breast Cancer

05 August 2021: Database Analysis

Yanni Song ^12BCEFG , Chaojing Zheng ^3C , Yangbao Tao ^3D , Rui Huang ^3E , Qian Zhang ^4AE*

DOI: 10.12659/MSM.929615

Med Sci Monit 2021; 27:e929615

Table 1 Cox regression analysis of risk scores and clinicopathological factors for patients’ overall survival.

Characteristics	Univariate		Multivariate
Characteristics	HR (95%CI)	P	HR (95%CI)	P
Age (≥62 vs	2.01 (1.77–2.27)		2.02 (1.73–2.37)
Risk score (high vs low)	1.48 (1.32–1.67)		1.23 (1.08–1.39)	0.002
Hormone therapy (yes vs no)	1.28 (1.13–1.44)		0.93 (0.79–1.09)	0.372
Chemotherapy (yes vs no)	1.23 (1.06–1.43)	0.007	1.14 (0.91–1.42)	0.261
Radiotherapy (yes vs no)	0.84 (0.74–0.94)	0.003	0.78 (0.68–0.89)
Histologic grade
1	1		1
2	1.28 (1–1.64)	0.046	1.07 (0.69–1.67)	0.764
3	1.63 (1.28–2.07)		0.96 (0.56–1.64)	0.878
ER Status (positive vs negative)	0.85 (0.74–0.98)	0.022	0.91 (0.74–1.11)	0.347
PR Status (positive vs negative)	0.79 (0.7–0.89)		0.9 (0.78–1.04)	0.169
HER2 Status (positive vs negative)	1.45 (1.22–1.73)		1.36 (1.13–1.65)	0.001
Menopausal State (pre vs post)	0.59 (0.5–0.7)		0.87 (0.71–1.07)	0.192
Tumor Laterality (right vs left)	0.93 (0.82–1.05)	0.252
NPI
≤2.4	1		1
(2.4–3.4]	0.97 (0.75–1.24)	0.787	0.87 (0.52–1.46)	0.609
(3.4–5.4]	1.39 (1.1–1.74)	0.005	1.14 (0.6–2.16)	0.688
≥5.4	3.07 (2.35–4.01)		1.51 (0.65–3.51)	0.337
No. of positive LN
0	1		1
1–3	1.36 (1.19–1.56)		1.21 (0.98–1.5)	0.076
4–9	2.14 (1.78–2.58)		1.51 (1.03–2.2)	0.034
≥10	4.27 (3.38–5.38)		2.48 (1.62–3.79)
Tumor Size (>23 vs ≤23)	1.86 (1.65–2.1)		1.53 (1.35–1.75)
CI – confidence interval; ER – estrogen receptor; HER2 – human epidermal growth factor receptor 2; HR – hazard ratio; LN – lymph node; NPI – Nottingham prognostic index; PR – progesterone receptor.